IDEAYA Biosciences, Inc.

NasdaqGS:IDYA Stock Report

Market Cap: US$1.9b

IDEAYA Biosciences Management

Management criteria checks 3/4

IDEAYA Biosciences' CEO is Yujiro Hata, appointed in Jun 2015, has a tenure of 9.67 years. total yearly compensation is $6.00M, comprised of 10% salary and 90% bonuses, including company stock and options. directly owns 0.78% of the company’s shares, worth $15.00M. The average tenure of the management team and the board of directors is 2.1 years and 6.3 years respectively.

Key information

Yujiro Hata

Chief executive officer

US$6.0m

Total compensation

CEO salary percentage10.0%
CEO tenure9.7yrs
CEO ownership0.8%
Management average tenure2.1yrs
Board average tenure6.3yrs

Recent management updates

Recent updates

Ideaya Biosciences: Potential Registration-Enabling Darovasertib Study Coming

Feb 10

We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth

Jan 03
We Think IDEAYA Biosciences (NASDAQ:IDYA) Can Afford To Drive Business Growth

Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash

Dec 04

Ideaya Biosciences Advances Synthetic Lethality With IDE397 Success

Sep 20

Ideaya Biosciences: Poised For Success In Bladder And Lung Cancer?

Jul 08

Ideaya Biosciences Continues Its Pursuit Of 'Synthetic Lethality'

Jun 18

Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?

Feb 22
Is IDEAYA Biosciences (NASDAQ:IDYA) A Risky Investment?

Ideaya Biosciences: A Strong Bet In Targeted Oncology

Feb 16

Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week

Nov 09
Analysts Are Betting On IDEAYA Biosciences, Inc. (NASDAQ:IDYA) With A Big Upgrade This Week

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Oct 03
Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans

Jul 04
IDEAYA Biosciences (NASDAQ:IDYA) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

Mar 10
We're Not Very Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Rate

Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Nov 04
Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation

Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data

Oct 06

Ideaya Biosciences slides 8.5% aftermarket on $80M stock offering

Sep 14

Ideaya wins first milestone in GSK deal as cancer drug reaches clinical trials

Aug 29

CEO Compensation Analysis

How has Yujiro Hata's remuneration changed compared to IDEAYA Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024n/an/a

-US$274m

Sep 30 2024n/an/a

-US$178m

Jun 30 2024n/an/a

-US$154m

Mar 31 2024n/an/a

-US$129m

Dec 31 2023US$6mUS$598k

-US$113m

Sep 30 2023n/an/a

-US$103m

Jun 30 2023n/an/a

-US$74m

Mar 31 2023n/an/a

-US$68m

Dec 31 2022US$3mUS$570k

-US$59m

Sep 30 2022n/an/a

-US$53m

Jun 30 2022n/an/a

-US$66m

Mar 31 2022n/an/a

-US$55m

Dec 31 2021US$4mUS$544k

-US$50m

Sep 30 2021n/an/a

-US$37m

Jun 30 2021n/an/a

-US$30m

Mar 31 2021n/an/a

-US$31m

Dec 31 2020US$2mUS$510k

-US$34m

Sep 30 2020n/an/a

-US$40m

Jun 30 2020n/an/a

-US$46m

Mar 31 2020n/an/a

-US$44m

Dec 31 2019US$2mUS$457k

-US$42m

Sep 30 2019n/an/a

-US$40m

Jun 30 2019n/an/a

-US$42m

Mar 31 2019n/an/a

-US$38m

Dec 31 2018US$2mUS$420k

-US$34m

Compensation vs Market: Yujiro's total compensation ($USD6.00M) is about average for companies of similar size in the US market ($USD5.37M).

Compensation vs Earnings: Yujiro's compensation has increased whilst the company is unprofitable.

CEO

Yujiro Hata (50 yo)

9.7yrs

Tenure

US$5,995,440

Compensation

Mr. Yujiro S. Hata is Director since November 2024 at Hexagon Bio, Inc. He serves as an Independent Director at Enanta Pharmaceuticals, Inc. since August 29, 2021. He is a Co-Founder of IDEAYA Biosciences,...

Leadership Team

NamePositionTenureCompensationOwnership
Yujiro Hata
President9.7yrsUS$6.00m0.78%
$ 15.0m
Andres Briseno
Principal Accounting Officer4.1yrsUS$1.41m0.028%
$ 542.8k
Michael White
Chief Scientific Officer3.3yrsUS$2.76mno data
Darrin Beaupre
Chief Medical Officer2.3yrsUS$1.81m0%
$ 0
Joshua Bleharski
Chief Financial Officerno datano datano data
Paul Barsanti
Chief Technology Officer2.1yrsno datano data
Douglas Snyder
Senior VP & General Counselless than a yearno datano data
Francine Zelaya
Vice President & Head of Human Resourcesless than a yearno datano data
Mick O'Quigley
Chief of Staff & Clinical Development2.9yrsno datano data
Daniel Simon
Chief Business Officerless than a yearno datano data
Stuart Dorman
Chief Commercial Officerless than a yearno datano data

2.1yrs

Average Tenure

57yo

Average Age

Experienced Management: IDYA's management team is considered experienced (2.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Yujiro Hata
President9.7yrsUS$6.00m0.78%
$ 15.0m
Wendy Yarno
Independent Director5.2yrsUS$358.02k0%
$ 0
Jeffrey Stein
Independent Director9.3yrsUS$363.02k0.0050%
$ 94.7k
Susan Kelley
Independent Director4yrsUS$349.52k0%
$ 0
Frank McCormick
Chair of Scientific Advisory Board6yrsno datano data
Scott William Morrison
Independent Director6.6yrsUS$364.52k0%
$ 0
Catherine Mackey
Independent Director2.8yrsUS$350.52k0%
$ 0
Trey Ideker
Member of Scientific Advisory Board8.8yrsno datano data
William Sellers
Member of Scientific Advisory Board6yrsno datano data
Elizabeth Swisher
Member of Scientific Advisory Board8.8yrsno datano data
Terry Rosen
Independent Chairman of the Board9.1yrsUS$369.52k0.019%
$ 361.7k
Malcolm Hampton
Independent Director4.7yrsUS$349.52k0%
$ 0

6.3yrs

Average Tenure

67.5yo

Average Age

Experienced Board: IDYA's board of directors are considered experienced (6.3 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/22 16:43
End of Day Share Price 2025/02/21 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

IDEAYA Biosciences, Inc. is covered by 24 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu KumarBaird
Zhiqiang ShuBerenberg
Justin ZelinBTIG